Get the Stockscreener App
38.79
2.35%
0.89
After Hours:
38.90
0.11
+0.28%
Harrow Inc stock is traded at $38.79, with a volume of 367.40K.
It is up +2.35% in the last 24 hours and up +13.75% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$37.90
Open:
$38
24h Volume:
367.40K
Relative Volume:
0.53
Market Cap:
$1.44B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-237.25
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+5.61%
1M Performance:
+13.75%
6M Performance:
-1.65%
1Y Performance:
+63.05%
1-Day Range:
$37.93
$38.98
1-Week Range:
$35.50
$38.98
52-Week Range:
$21.12
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
38.79 | 1.41B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (HROW) Partners with LogiCare3PL for Distribution Services - GuruFocus
Harrow Taps LogiCare3PL as Distribution Partner - marketscreener.com
LogiCare3PL Selected as Distribution Partner by Harrow - ChartMill
Harrow: Probably A Short-Term Market Overreaction (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (NASDAQ:HROW) Presents a Growth and Breakout Opportunity - ChartMill
Harrow announces $50M add-on senior notes offering - MSN
Assessing Harrow (HROW) Valuation After US$8.1 Million In Recent Insider Stock Sales - Yahoo Finance
Harrow Inc (HROW) Stock Up 3.3% and Still Undervalued -- GF Scor - GuruFocus
Harrow Inc (HROW) Shares Fall 3.6% -- What GF Score of 86 Tells Investors - GuruFocus
How Harrow Health Inc. 8.625% Senior Notes Due 2026 (HROWL) Affects Rotational Strategy Timing - Stock Traders Daily
BTIG to Host Virtual Meeting Focused on HROW This April - GuruFocus
HROW Virtual Meeting Scheduled for April 14 - GuruFocus
Working capital per share of Harrow, Inc. – FWB:3IP - TradingView
Cash per share of Harrow, Inc. – FWB:3IP - TradingView — Track All Markets
Long term debt to total assets ratio of Harrow, Inc. – FWB:3IP - TradingView
BTIG Maintains Buy on Harrow Health, Inc. (HROW) March 2026 - Meyka
Buy Signal: Can Harrow Inc maintain sales growth2026 Historical Comparison & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Harrow (HROW) Receives Analyst Rating Reiteration with Lowered P - GuruFocus
B. Riley Securities Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
B. Riley Lowers Price Target on Harrow to $65 From $74, Keeps Buy Rating - marketscreener.com
HROW Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
HROW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum - MSN
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Institution Moves: Is Harrow Inc attractive for institutional investors2026 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal? - AOL.com
HROW6348836 Bond Coupon Analysis — Rate & Payments - TradingView
HROW6348836 Bond Risk Analysis - TradingView — Track All Markets
HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow prices $50M senior unsecured notes due 2030 at 8.625% - MSN
Layoff Watch: Will Harrow Inc stock recover after earnings2026 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Will Harrow Inc benefit from geopolitical trends2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Discipline and Rules-Based Execution in HROW Response - Stock Traders Daily
What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders - Yahoo Finance
Harrow Health Expands Senior Notes Offering for Growth - TipRanks
Harrow Raises $50 Million Via Additional 8.625% Senior Notes Due 2030; Signs Purchase Agreement and Indenture - TradingView
Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030 - Stock Titan
Vanguard disaggregates holdings — Harrow Inc (HROW) reports 0 shares - Stock Titan
Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises - Sahm
Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
Is Harrow Inc currently under institutional pressure2026 Trading Volume Trends & AI Driven Price Forecasts - baoquankhu1.vn
HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price - ChartMill
HROW6348836 Bond Price and Chart — FINRA:HROW6348836 - TradingView — Track All Markets
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth - Bitget
Harrow Announces $50 Million Senior Unsecured Notes Offering Due 2030 to Accelerate Growth and Product Development 12 - Minichart
Harrow Health Prices $50 Million Senior Notes Offering - TipRanks
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):